SUO 2017 Bladder Cancer

Viewing 1-20 of 64 articles

SUO 2017: Cost Effective Analysis of Neoadjuvant Chemotherapy Prior to Radical Cystectomy in T2 Bladder Cancer

SUO 2017: A Nationwide Analysis of Complete Urinary Tract Extirpation

SUO 2017: Comparing Effective Treatment Strategies for Squamous Cell Carcinoma of the Bladder

SUO 2017: Mutations And Gene Expression Differences Between African Americans And Non-African Americans With Urothelial Cell Carcinoma

SUO 2017: Oncologic Outcomes Comparing Open and Robot-Assisted Laparoscopic Radical Cystectomy for Bladder Cancer

SUO 2017: Inaccuracy of Clinical Staging After Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

SUO 2017: Chemotherapy Prior to Radical Nephroureterectomy in Patients with Advanced Upper Tract Urothelial Carcinoma

SUO 2017: Hospital Readmissions after Radical Cystectomy: The Impact of an Enhanced Recovery Pathway

SUO 2017: Impact of Variant Histology on Response to Neoadjuvant Chemotherapy for Bladder Cancer

SUO 2017: Patient-Centered Health Information Self-Education Tool Supporting Recovery After Cystectomy and Urinary Diversion

SUO 2017: Enhanced Recovery After Surgery (ERAS) Protocol for Patients Undergoing Radical Cystectomy

SUO 2017: Papillary Urothelial Neoplasia of Low Malignant Potential (PUNLMP) Recurrence Rates

SUO 2017: Quality Improvement Initiative for Patients with Muscle-Invasive Bladder Cancer

SUO 2017: Multimodal Treatment With Chemotherapy And Radical Nephroureterectomy May Improve Overall Survival In Patients With Clinically Positive Lymph Node Disease

SUO 2017: Refining Selection Criteria for Neoadjuvant Chemotherapy - MIBC

SUO 2017: Prehabilitation for Cystectomy Patients - The Impact of Bladder Boot Camp

SUO 2017: Utilization of BCG for Non-Muscle Invasive Bladder Cancer in an Era of BCG Supply Shortages

SUO 2017: External Validation of EORTC Bladder Cancer Risk Calculator in a Contemporary US Population

SUO 2017: Inaccuracy of Clinical Staging After Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

SUO 2017: Neoadjuvant Chemotherapy with Dose Dense MVAC, Associated with Higher Down Staging and Pathologic T0 Rates after Radical Cystectomy

1
2
3
4